PharmaCyte Biotech (PMCB) cancels erroneous stock option grant
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
WEINSTEIN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Robert Weinstein reported a correction to a stock option award. A previously reported Stock Option (Right to Buy) grant dated 2026-03-31 was made in error and has been cancelled, leaving 0 derivative shares transacted and 0 shares remaining from that specific grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
WEINSTEIN ROBERT
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Stock Option (Right to Buy) | 0 | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Transaction date: 2026-03-31
Derivative shares transacted: 0
Shares following transaction: 0
+1 more
4 metrics
Transaction date
2026-03-31
Date associated with the corrected stock option grant entry
Derivative shares transacted
0
Stock Option (Right to Buy) shares reported in the transaction
Shares following transaction
0
Derivative shares from this grant held after cancellation
Derivative transaction count
1
Number of derivative security transactions reported in this amendment
Key Terms
Stock Option (Right to Buy), derivative security, transaction code J, Form 4/A
4 terms
Stock Option (Right to Buy) financial
"Security title reported as Stock Option (Right to Buy) for the grant"
derivative security financial
"Recorded as a derivative security linked to PharmaCyte common stock"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
transaction code J regulatory
"Classified under transaction code J for other acquisition or disposition"
Form 4/A regulatory
"Amended insider report filed on Form 4/A for this correction"
Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did PharmaCyte Biotech (PMCB) report about Robert Weinstein's stock option grant?
PharmaCyte Biotech reported that a stock option grant to director Robert Weinstein was made in error and cancelled. The amended disclosure shows 0 derivative shares were transacted and 0 shares remain from that specific Stock Option (Right to Buy) grant.
What type of security is involved in Robert Weinstein's PharmaCyte Biotech (PMCB) report?
The report involves a Stock Option (Right to Buy), categorized as a derivative security linked to PharmaCyte common stock. That specific option grant was later identified as having been made in error and is now reported as cancelled with zero shares.
What transaction code is used in this PharmaCyte Biotech (PMCB) insider update?
The transaction uses code J, described as an other acquisition or disposition event. In this case, the accompanying footnote clarifies that the previously reported stock option grant was erroneous and has been cancelled rather than representing a new acquisition.
Does Robert Weinstein retain any options from the cancelled PharmaCyte Biotech (PMCB) grant?
No, Robert Weinstein reports holding 0 shares from the cancelled option grant. The total shares following the transaction for this Stock Option (Right to Buy) entry are listed as zero, confirming no remaining derivative position from this specific grant.